Eaton Corporation plc vs Revvity Inc — how do they compare? Eaton Corporation plc trades at $429.65 (market cap $164.88B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Eaton Corporation plc is far larger — about 9.7× Revvity Inc's market cap, and Eaton Corporation plc pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Revvity Inc for 12 Days on average.
| ETN | RVTY | |
|---|---|---|
Market Cap | $164.88B | $16.98B |
Volume | 2,535,086 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $459.96 | $157.36 |
52-Week Low | $315.82 | $82.26 |
Typical Hold Time | 31 Days | 12 Days |
Enterprise Value | $185.51B | $19.30B |
Dividend Yield | 1.04% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $429.65, down 0.39% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company maintains strong fundamentals with 12.75% net income margin and 19.71% ROE, supported by strategic acquisitions in data center and aerospace markets. Analyst consensus remains strongly bullish with a $502.38 price target, representing 17% upside potential from current levels.
ETN's outlook remains positive driven by data center demand and grid modernization trends, though elevated valuation multiples (P/E 43.23) and bearish technical signals warrant caution. The stock faces execution risks from recent acquisitions and competitive pressure in the electrical equipment sector, but strong institutional support and consistent earnings performance support the bullish analyst stance.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →